Tarsus Pharmaceuticals Inc Total Assets
Tarsus Pharmaceuticals Inc total assets. Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) holds total assets worth $611.14 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TARS cash generation efficiency for how efficiently the company converts equity into cash flow.
Total Assets of Tarsus Pharmaceuticals Inc (2018–2025)
Total assets of Tarsus Pharmaceuticals Inc from 2018 to 2025. This chart illustrates how Tarsus Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Tarsus Pharmaceuticals Inc for real-time trading data and today's change.
Tarsus Pharmaceuticals Inc - Asset Composition Analysis
Tarsus Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Tarsus Pharmaceuticals Inc total assets breakdown as of December 2025. Tarsus Pharmaceuticals Inc's total assets of $611.14 Million consist of 93.0% current assets and 7.0% non-current assets. Explore working capital position of Tarsus Pharmaceuticals Inc to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.7% |
| Accounts Receivable | $87.11 Million | 15.5% |
| Inventory | $4.37 Million | 0.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.37 Million | 1.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Tarsus Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tarsus Pharmaceuticals Inc's current assets represent 93.0% of total assets in 2025, a decrease from 99.8% in 2018.
- Cash Position: Cash and equivalents constituted 32.7% of total assets in 2025, down from 98.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 15.5% of total assets.
Tarsus Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Tarsus Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Tarsus Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.20 | 5.26 | 18.05 |
| Quick Ratio | 3.17 | 5.21 | 18.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $386.24 Million | $384.18 Million | $176.72 Million |
Tarsus Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Tarsus Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.05 |
| Latest Market Cap to Assets Ratio | 5.79 |
| Asset Growth Rate (YoY) | 49.1% |
| Total Assets | $562.16 Million |
| Market Capitalization | $3.26 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Tarsus Pharmaceuticals Inc's assets at a significant premium (5.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Tarsus Pharmaceuticals Inc's assets grew by 49.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tarsus Pharmaceuticals Inc (2018–2025)
The table below shows the annual total assets of Tarsus Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $562.16 Million | +49.12% |
| 2024-12-31 | $376.99 Million | +42.00% |
| 2023-12-31 | $265.49 Million | +16.51% |
| 2022-12-31 | $227.86 Million | +27.36% |
| 2021-12-31 | $178.91 Million | +4.03% |
| 2020-12-31 | $171.97 Million | +194.90% |
| 2019-12-31 | $58.32 Million | +2341.02% |
| 2018-12-31 | $2.39 Million | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more